Literature DB >> 1164075

Congenital cardiac anomalies: one-stage repair in infancy.

D B Doty, R M Lauer, J L Ehrenhaft.   

Abstract

A proposed preferred treatment plan consisting of one-stage operative repair of congenital cardiac anomalies whenever complete correction was feasible and operative intervention required was tested during the period February 1, 1972, to September 15, 1974. Experience with 74 patients aged 14 hours to 24 months allows some conclusions to be made regarding the advisability of this approach. For patients with ventricular defect and tetralogy of Fallot, this approach has quite acceptable results and certainly is more direct than palliative operations and second-stage repair. The hypothesis is more difficult to justify in patients with transposition of the great arteries. By avoiding repair in patients under 4 months of age and using a better technique for placement of the intraatrial partition, improved results are anticipated. In the miscellaneous group of anomalies, results depend upon the complexity of the defect and the ability to achieve accurate anatomical correction. After an early mortality of 20% and some late deaths, survival and improvement resulted in 51 of these babies. These results justify persistence in the choice of one-stage correction when operative intervention is required.

Entities:  

Mesh:

Year:  1975        PMID: 1164075     DOI: 10.1016/s0003-4975(10)64224-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Repair of ventricular septal defect in the first two years of life using profound hypothermia-circulatory arrest techniques.

Authors:  B G Barratt-Boyes; J M Neutze; P M Clarkson; G C Shardey; P W Brandt
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

2.  Anomalous origin of the right pulmonary artery from the ascending aorta associated with aortopulmonary window.

Authors:  G Gula; C Chew; R Radley-Smith; M Yacoub
Journal:  Thorax       Date:  1978-04       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.